Want to see IN:GLAND full AI Analyst Report?

Gland Pharma Ltd. (GLAND) Price & Analysis

1 Followers

GLAND Stock Chart & Stats

₹2378.35

₹47.30(1.99%)

At close: Jul 27 4:00 PM EDT

₹2378.35

₹47.30(1.99%)

Day’s Range― - ―

52-Week Range₹1,575.00 - ₹2,586.00

Previous CloseN/A

Volume300.62K

Average Volume (3M)9.08K

Market Cap

₹413.13B

Enterprise Value₹249.21K

Total Cash (Recent Filing)₹34.33B

Total Debt (Recent Filing)₹2.84B

Price to Earnings (P/E)40.1

Beta0.68

Next Earnings

Aug 10, 2026

EPS Estimate

18.01

Next Dividend Ex-DateN/A

Dividend Yield1.52%

Share Statistics

EPS (TTM)62.36

Shares Outstanding164,959,690

10 Day Avg. Volume10,062

30 Day Avg. Volume9,084

Financial Highlights & Ratios

PEG Ratio0.58

Price to Book (P/B)2.70

Price to Sales (P/S)4.35

P/FCF Ratio37.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,080.00

Price Target Upside-12.54% Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)74.07

Revenue Forecast (FY)₹73.68B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetExtremely low leverage and a large equity base provide durable financial flexibility: supports investment in sterile capacity, absorbs demand or pricing shocks, and enables opportunistic M&A or R&D funding without materially increasing financing risk over the next 2–6 months.

Improving Cash GenerationA sharp rise in operating cash flow and ~85% free cash flow growth indicate improving internal funding ability. Sustained FCF supports capital reinvestment into sterile injectables capacity, funds working capital needs, and reduces dependence on external financing over the medium term.

Specialized Sterile-injectables / CDMO PositioningFocus on sterile and complex injectables creates structural advantages: high regulatory barriers, specialized facilities, and long-term supply relationships with global pharma firms. This niche positioning supports stable revenue streams and customer stickiness over multiple quarters.

Bears Say

Gross Margin VolatilityA sharp drop in gross margin suggests either adverse product mix, pricing pressure, or cost escalation. Persistent margin volatility undermines earnings predictability, reduces reinvestment capacity, and raises execution risk for sustaining return levels in the medium term.

Net Income Below Prior PeakRevenue growth without recovery of net income versus FY2022 implies margin compression or higher operating costs. This limits improvement in ROE and shareholder returns, signaling that topline growth alone may not translate to sustained profitability gains.

Moderate Cash Conversion And CoverageCash conversion below EBITDA and FCF at ~60% of net income indicate lower earnings quality and potential working-capital or capex drains. This constrains the company's ability to fund growth or payouts consistently even as headline FCF improved.

Gland Pharma Ltd. News

Gland Pharma files FY26 Business Responsibility and Sustainability Report

Gland Pharma Ltd. ( ($IN:GLAND) ) has shared an announcement. Gland Pharma Limited has submitted its Business Responsibility...

3d ago

GLAND

Gland Pharma Sets 48th AGM, Announces Dividend and KYC Update Drive

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an announcement. Gland Pharma Limited has scheduled its 48th Annual...

3d ago

GLAND

Gland Pharma Schedules Q1 FY27 Earnings Call for August 10

Gland Pharma Ltd. ( ($IN:GLAND) ) has shared an update. Gland Pharma Limited has scheduled an earnings conference...

10d ago

GLAND

Gland Pharma Schedules Analyst and Institutional Investor Meetings

Gland Pharma Ltd. ( ($IN:GLAND) ) has provided an announcement. Gland Pharma Ltd. has notified stock exchanges that...

1M ago

GLAND

Gland Pharma Seeks Shareholder Nod to Reappoint Independent Director via E-Voting

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma has initiated a postal...

4M ago

GLAND

Gland Pharma Schedules Investor Meet Arranged by Goldman Sachs

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an update. Gland Pharma Limited has notified the stock exchanges...

5M ago

GLAND

Gland Pharma Schedules Series of Investor and Analyst Meetings in February 2026

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an announcement. Gland Pharma Limited has announced a series of...

6M ago

GLAND

Gland Pharma uploads Q3 FY26 earnings call recording for investors

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma Limited has notified the...

6M ago

GLAND

Gland Pharma Schedules Investor Meetings for November 2025

Gland Pharma Ltd. ( ($IN:GLAND) ) has shared an update. Gland Pharma Limited has announced a series of...

9M ago

GLAND

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an announcement. Gland Pharma Limited has announced the appointment of...

11M ago

GLAND

GLAND FAQ

What was Gland Pharma Ltd.’s price range in the past 12 months?

Gland Pharma Ltd. lowest stock price was ₹1575.00 and its highest was ₹2586.00 in the past 12 months.

What is Gland Pharma Ltd.’s market cap?

Gland Pharma Ltd.’s market cap is ₹413.13B.

When is Gland Pharma Ltd.’s upcoming earnings report date?

Gland Pharma Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 7 days.

How were Gland Pharma Ltd.’s earnings last quarter?

Gland Pharma Ltd. released its earnings results on May 15, 2026. The company reported ₹22.3 earnings per share for the quarter, beating the consensus estimate of ₹16.252 by ₹6.048.

Is Gland Pharma Ltd. overvalued?

According to Wall Street analysts Gland Pharma Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gland Pharma Ltd. pay dividends?

Gland Pharma Ltd. pays a Annually dividend of ₹20 which represents an annual dividend yield of 1.52%. See more information on Gland Pharma Ltd. dividends here

What is Gland Pharma Ltd.’s EPS estimate?

Gland Pharma Ltd.’s EPS estimate is 18.01.

How many shares outstanding does Gland Pharma Ltd. have?

Gland Pharma Ltd. has 164,959,690 shares outstanding.

What happened to Gland Pharma Ltd.’s price movement after its last earnings report?

Gland Pharma Ltd. reported an EPS of ₹22.3 in its last earnings report, beating expectations of ₹16.252. Following the earnings report the stock price went down -1.48%.

Which hedge fund is a major shareholder of Gland Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:GLAND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gland Pharma Ltd.

Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Gland Pharma Ltd. (GLAND) Earnings & Revenues

Historic Earnings Reports

GLAND Stock 12 Month Forecast

Average Price Target

₹2,080.00

▼(-12.54% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1705":"₹1,705","1905":"₹1,905","2105":"₹2,105","2305":"₹2,305","2505":"₹2,505"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.08K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1705,1905,2105,2305,2505],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2504.4,2471.753846153846,2439.1076923076926,2406.4615384615386,2373.8153846153846,2341.169230769231,2308.523076923077,2275.876923076923,2243.2307692307695,2210.5846153846155,2177.9384615384615,2145.292307692308,2112.646153846154,{"y":2080,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2504.4,2471.753846153846,2439.1076923076926,2406.4615384615386,2373.8153846153846,2341.169230769231,2308.523076923077,2275.876923076923,2243.2307692307695,2210.5846153846155,2177.9384615384615,2145.292307692308,2112.646153846154,{"y":2080,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2504.4,2471.753846153846,2439.1076923076926,2406.4615384615386,2373.8153846153846,2341.169230769231,2308.523076923077,2275.876923076923,2243.2307692307695,2210.5846153846155,2177.9384615384615,2145.292307692308,2112.646153846154,{"y":2080,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1960.93,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1868.8,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1980.55,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1929.5,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1726.2,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1715.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1897.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1706.65,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1751,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2292.5,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2463.15,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2504.4,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >